Dotmatics Ltd., a Herts, England-based scientific informatics software and services company, is to acquire BioBright LLC, a Boston, MA-based leader in automating the flow of data from laboratory instruments to a secure cloud.
The amount of the deal was nor disclosed.
The acquisition will create a combination of lab data capture, data processing, electronic lab notebook (ELN) and data analytics capability from a single supplier. All data coming from instruments, users or CROs will flow into a centralized informatics platform and through end-to-end workflows, allow scientists to increase lab efficiency and make informed decisions. It will also provide the data foundation which will be key to improving innovation through better informed decision-making for scientists aided by next generation AI and machine learning. The combined portfolio will be available from Dotmatics, meaning that customers will have the ability to automate their research data workflows without needing to manage multiple vendor relationships.
Led by Charles Fracchia, Co-Founder and Chief Executive Officer, BioBright is a scientific lab data automation company dedicated to creating the smart laboratory of the future driven by the move to data-centric research. The company’s solutions enable scientists to automate the collection of data from in-house and externally networked sources, and then standardize and analyze crucial experimental data with validation and integrity checks built in. It began operations in 2015 and was funded early on by the Defense Advanced Research Projects Agency to create a secure data collection platform for complex biological data.
Led by Dr Stephen Gallagher, Co-Founder and Chief Executive Officer, Dotmatics is a scientific informatics software and services company that provides a portfolio of tools for fully automated, end-to-end workflows including data acquisition, knowledge management, data storage, enterprise querying and reporting, and data analytics and visualization. Customers include many of the world’s leading pharmaceutical, biotechnology, contract research, chemicals and materials companies.
The company is headquartered in the UK with offices in USA, Korea and Japan and is backed by growth equity firm Scottish Equity Partners.